References
Karkouti K, Beattie WS, Arellano R, Aye T, Bussieres JS, Callum JL, Cheng D, Heinrich L, Kent B, Lee TW, MacAdams C, Mazer CD, Muirhead B, Rochon AG, Rubens FD, Sawchuk C, Wang S, Waters T, Wong BI, Yau TM (2008) Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 118:331–338
Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA (2008) Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 34:73–92
Veldman A, Neuhaeuser C, Akintuerk H, Thul J, Gehron J, Schranz D, Michel-Behnke I (2007) rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth 17:1176–1181
Agarwal HS, Bennett JE, Churchwell KB, Christian KG, Drinkwater DC Jr, He Y, Taylor MB (2007) Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 84:161–168
Gandhi MJ, Pierce RA, Zhang L, Moon MR, Despotis GJ, Moazami N (2007) Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant. J Cardiothorac Surg 2:32
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schneider, A.G., Perez, MH., Tozzi, P. et al. Recombinant factor VIIa for intractable life-threatening bleeding in patients with circulatory assist devices. Intensive Care Med 36, 1620–1621 (2010). https://doi.org/10.1007/s00134-010-1937-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-010-1937-y